PetIQ, Inc. Revises Earnings Guidance for the Full Year 2023
August 09, 2023 at 01:36 am IST
Share
PetIQ, Inc. revised earnings guidance for the full year 2023. For the full year 2023, the company is raising its outlook previously provided, and now expects: Net sales of $1,010 million to $1,050 million, an increase of approximately 12.0% compared to 2022 based on the mid-point of the guidance.
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
PETIQ, INC. 
